SHERIDAN, WYOMING – August 10, 2025 – Globus Medical, Inc. (NYSE: GMED) reported strong second-quarter 2025 results, achieving record non-GAAP earnings per share and double-digit revenue growth, driven by its U.S. Spine business and strategic integration of Nevro. The performance underscores the company’s operational discipline and its continued push to expand robotic-assisted surgery adoption.
Double-Digit Revenue Growth Across Core Segments
Worldwide net sales reached $745.3 million, an 18.4% year-over-year increase, or 17.6% on a constant currency basis. U.S. net sales rose 20.3%, while international revenue grew 11% as reported. The company’s Musculoskeletal Solutions segment generated $710.2 million, with Enabling Technologies contributing $35.2 million after a modest rebound in demand.
Operational Leverage and Profitability Milestones
GAAP net income surged to $202.8 million, supported by a $110.6 million bargain purchase gain from the Nevro acquisition and a $34.8 million tax benefit. Non-GAAP diluted EPS climbed 14.1% to $0.86, reflecting strong base business performance. Free cash flow for the quarter was $31.3 million, bolstering the company’s ability to fund new product launches and salesforce expansion.
- Gross margin: 63.3% (GAAP), 67.4% (non-GAAP)
- Adjusted EBITDA: $208.7 million, representing 28% of net sales
- Cash & equivalents: $229.4 million at quarter-end
CEO Highlights Robotic Surgery Strategy
“Q2 results were led by our U.S. Spine business, growing 5.7% as reported and 7.4% on a day-adjusted basis,” said Keith Pfeil, President and CEO. “We remain focused on accelerating deal timelines from our pipeline to make robotic-assisted surgery the standard of care moving ahead. These efforts will drive a return to above-market growth across our portfolio.”
Integration of Nevro to Expand Pain and Neuromodulation Offerings
The Nevro acquisition, closed earlier this quarter, contributed $94.6 million in revenue. CFO Kyle Kline confirmed the company is “diligently working to identify and execute synergy actions” to align Nevro’s neuromodulation technologies with Globus Medical’s commercial infrastructure, enhancing cross-specialty sales opportunities.
Market Context: Spine and Orthopedic Robotics
The spinal implant market continues to shift toward digitally integrated, navigation-enabled systems, with hospitals seeking to improve accuracy, reduce operative times, and differentiate in competitive orthopedic service lines. Globus Medical’s enabling technologies—robotics, navigation, and imaging—are positioned to benefit from this shift, especially as capital equipment investments rebound post-pandemic.
2025 Guidance Reaffirmed
Globus Medical reiterated its full-year 2025 revenue outlook of $2.80–$2.90 billion and non-GAAP diluted EPS of $3.00–$3.30. The company’s growth trajectory remains anchored in:
- Launching next-generation spine and orthopedic products
- Driving robotic account adoption
- Recruiting competitive sales talent
- Leveraging M&A synergies for portfolio expansion
As the musculoskeletal solutions market grows more technology-driven, Globus Medical’s focus on integrated hardware-software ecosystems and surgeon engagement is expected to sustain its competitive advantage.
Learn more at www.globusmedical.com.